FDA Approves 1st New Sunscreen Ingredient (Bemotrizinol) in Decades: What It Means for Your Skin

For the first time in more than two decades, the U.S. Food and Drug Administration (FDA) has approved a new sunscreen active ingredient, a decision many dermatologists, skin cancer experts and public health advocates have been pushing for years. The newly approved ingredient, bemotrizinol, has been widely used in Europe, Australia, Asia and other parts of the world for decades, earning a reputation as one of the most effective and stable ultraviolet (UV) filters available.

Yet until now, Americans have not had access to sunscreens formulated with it.

The FDA’s decision could mark a significant turning point for sun protection in the United States. Experts say bemotrizinol sunscreen products may offer stronger broad-spectrum protection against both ultraviolet A (UVA) and ultraviolet B (UVB) rays, improved stability in sunlight, and more formulation flexibility compared to many currently available sunscreen options.

The approval also highlights a longstanding criticism of the U.S. sunscreen market: While sunscreen technology has advanced rapidly around the world, regulatory hurdles have limited Americans’ access to newer UV filters that have been safely used overseas for years.

Supporters of the move say bringing bemotrizinol to the U.S. could help close that gap and provide consumers with more effective choices for preventing sun damage, premature skin aging and skin cancer.

Ad

Here’s what you need to know about bemotrizinol, why dermatologists are excited and how bemotrizinol sunscreen could change sun protection in the U.S.

What is bemotrizinol?

Bemotrizinol, also known as BEMT and marketed by DSM-Firmenich under the name PARSOL® Shield, is a chemical UV filter that absorbs both UVA and UVB radiation.

Unlike many older sunscreen ingredients that primarily protect against one type of UV radiation, bemotrizinol offers broad-spectrum coverage across a wide range of wavelengths. This makes it highly effective at helping protect against:

• Sunburn
• Premature skin aging
• Hyperpigmentation
• DNA damage
• Skin cancer risk associated with UV exposure

For years, dermatologists and sunscreen researchers have pointed out that consumers in Europe and Asia had access to more advanced UV filters than Americans. Bemotrizinol has been one of the most sought-after ingredients because of its effectiveness, safety profile and cosmetic elegance.

Why is this such a big deal?

The FDA’s approval marks the first new sunscreen active ingredient added to the U.S. over-the-counter sunscreen monograph in more than two decades.

While sunscreen technology has advanced significantly around the world, the U.S. has lagged behind because sunscreen ingredients are regulated as over-the-counter drugs rather than cosmetics. This has made the approval process much longer and more expensive.

As a result, many popular international sunscreens have relied on newer UV filters unavailable to American consumers.

The FDA concluded that bemotrizinol meets safety and effectiveness standards and can now be used in approved sunscreen formulations for adults and children 6 months and older.

The Environmental Working Group, dermatologists, skin cancer advocates and public health experts have praised the decision as a major step forward for consumer access to better sun protection.

Bemotrizinol sunscreen vs. existing U.S. sunscreens

1. Superior broad-spectrum protection

One of the biggest advantages of bemotrizinol sunscreen is its ability to absorb both UVA and UVB rays.

UVB rays are primarily responsible for sunburn, while UVA rays penetrate deeper into the skin and contribute significantly to:

• Wrinkles
• Fine lines
• Loss of elasticity
• Hyperpigmentation
• Certain forms of skin cancer

Many currently approved U.S. chemical filters require multiple ingredients to achieve comprehensive broad-spectrum coverage. Bemotrizinol helps simplify and strengthen protection.

2. Exceptional photostability

A common challenge with some sunscreen ingredients is that they break down when exposed to sunlight.

Bemotrizinol is considered highly photostable, meaning it maintains its effectiveness even after prolonged UV exposure.

This can help provide more consistent protection throughout sun exposure and may improve overall sunscreen performance.

Ad

3. Minimal skin absorption

FDA-reviewed data found that bemotrizinol demonstrates very low absorption through the skin.

This is particularly noteworthy because some currently available chemical sunscreen ingredients have faced questions regarding systemic absorption into the bloodstream.

The FDA determined that bemotrizinol’s absorption profile supports its safety and effectiveness.

4. Low irritation potential

Experts note that bemotrizinol is generally well tolerated and rarely causes skin irritation.

Because of this favorable safety profile, the FDA approved it for use in children as young as 6 months old.

Is bemotrizinol safe?

According to the FDA’s review, yes.

The agency found sufficient evidence to classify bemotrizinol as generally recognized as safe and effective when used according to approved conditions.

Safety factors supporting approval include:

• Low skin absorption
• Low irritation potential
• Decades of international use
• Strong toxicology data
• Broad real-world safety experience

The ingredient has already been used in sunscreen products across Europe, Asia, Australia and Canada for many years, providing regulators with extensive safety data.

When will bemotrizinol sunscreen be available in the U.S.?

Although the approval is official, consumers may need to wait a little longer before seeing widespread availability.

The ingredient manufacturer, DSM-Firmenich, plans to market bemotrizinol in the United States as PARSOL® Shield. Several sunscreen brands have already indicated they are developing products that incorporate the ingredient.

Industry reports suggest that the first bemotrizinol sunscreen products could begin appearing later in 2026, with broader market adoption likely over the following years.

Does this mean mineral sunscreens are no longer necessary?

No.

Mineral sunscreens containing zinc oxide and titanium dioxide remain excellent options, especially for:

• Sensitive skin
• Babies and young children
• People prone to irritation
• Individuals seeking mineral-only formulations

However, bemotrizinol gives consumers another highly effective option and may help improve the wearability, feel and performance of future sunscreen products.

For many people, the best sunscreen is still the one they will use consistently every day.

Frequently asked questions

What is bemotrizinol?

Bemotrizinol is a broad-spectrum sunscreen ingredient that absorbs both UVA and UVB rays. It has been used internationally for decades and was approved by the FDA in 2026 as the first new U.S. sunscreen active ingredient in more than 20 years.

Is bemotrizinol sunscreen better?

Bemotrizinol sunscreen offers several advantages, including broad-spectrum UV protection, exceptional photostability, low skin absorption and low irritation potential. Whether it is “better” depends on individual needs, but many dermatologists consider it an important advancement in sunscreen technology.

Is bemotrizinol safe?

The FDA determined that bemotrizinol is generally recognized as safe and effective when used as directed. It has also been used safely in other countries for many years.

Can children use bemotrizinol sunscreen?

Yes. The FDA approval allows use in adults and children 6 months of age and older.

Why wasn’t bemotrizinol available in the U.S. before?

The U.S. regulates sunscreen ingredients as over-the-counter drugs, which requires extensive review and testing. This process has historically slowed the introduction of new sunscreen filters compared with other countries.

Key takeaways

• The FDA approved bemotrizinol as a new active sunscreen ingredient, the first addition to the U.S. sunscreen monograph since the late 1990s.
• Bemotrizinol provides broad-spectrum protection against both UVA and UVB rays.
• The ingredient has been used safely for decades in Europe, Asia, Australia and other countries.
• Research reviewed by the FDA found minimal skin absorption and low irritation potential, supporting its designation as generally recognized as safe and effective.
• Sunscreens containing bemotrizinol are expected to begin appearing in the U.S. market later in 2026.

Conclusion

The FDA’s approval of bemotrizinol represents one of the most significant sunscreen developments in the United States in more than two decades. With strong broad-spectrum protection, impressive photostability, minimal skin absorption and decades of international safety data, bemotrizinol sunscreen could help usher in a new era of more effective sun protection for Americans.

While no sunscreen ingredient is a substitute for comprehensive sun safety habits, the addition of bemotrizinol gives consumers and formulators another powerful tool in the fight against photoaging, sun damage and skin cancer. As new products arrive on store shelves, this long-awaited ingredient may finally help close the sunscreen innovation gap between the United States and the rest of the world.